Core business

Hanalytics Pte Ltd (BioMind®) is a deep learning company specialising in healthcare. The company develops AI medical applications to assist doctors diagnose medical conditions and recommend treatments. The company has a strong team of over 100 in-house deep learning scientists, medical experts, and research advisors from prestigious hospitals and universities.

In December 2018, BioMind® established the world’s first and largest AI research centre for neurological diseases. The research centre, CNCRC-Hanalytics Artificial Intelligence Research Centre for Neurological Disorders (CHAIN), researches and develops AI applications covering a wide spectrum of areas including Covid-19 pneumonia, brain tumors, vascular diseases, stroke, genetics, patient rehabilitation amongst many other conditions.

Products & services

BioMind® is a state-of-the-art diagnostic support system that uses deep learning technology to analyse MRI, MRA, CT, CTA and CTP images of the brain. It automatically recommends a diagnosis and report for doctors to review – all within seconds. The efficiency gains are significant when compared to the usual 30 minutes or more doctors usually take for analysis and reporting. Other noteworthy features include triaging, 3D reconstruction of large arteries, lesions quantification and localisation, prognosis of ICH, to name a few. The products are CE marked and can be used commercially.


Major HealthTech projects

In 2021, BioMind launches the iStroke project. This serves as an intelligent decision support tool to aid acute ischemic stroke (AIS) treatment.  AIS is a time-critical cerebrovascular disease with high incidence and mortality rate worldwide. Early recognition and treatment decision making of AIS stroke is critical to the appropriate management of stroke patients. With iStroke, we envision to augment clinicians in their efforts to reduce the preoperative decision-making time, thus allowing more patients to be managed at the right time.

Technical / technological capabilities

BioMind®  is jointly developed by over 200 world-renowned medical specialists and deep learning experts and trained on the biopsy-validated images “the ground truth”. Its signature feature includes analysing neurological disorders such as brain tumours, vascular diseases such as infarction, WMH, stenosis, and stroke-related medical conditions – which take up majority of the conditions determined through medical imaging. With the application of AI technology, not only can BioMind® analyse a large spectrum of neurological conditions, its technology can also be upgraded to analyse medical conditions of other body systems. BioMind® also has sophisticated image processing features like image segmentation and 3D reconstruction to assist in surgeries.

BioMind® has the ability to self-learn and improve through cycles of predictions and doctors’ revisions. This ability in turns assists doctors to reduce misdiagnosis and blind spots and improve efficiency of medical processes.

Main customers / collaborations

BioMind®’s key customer that can be disclosed include Beijing Tiantan Hospital, a global leader in neurology and neurosurgery. BioMind® is being used in the radiology, neurology and A&E departments for triaging, assisting in diagnosis and disease management. The solution has since been deployed to over 150 hospitals.

Looking for

OEM partnerships, PACs companies, distributors, grant projects.

Print this page Send by email

Empowering Health with Artificial Intelligence


Raymond Moh is the co-founder and CEO of BioMind®. Raymond graduated from the prestigious National University of Singapore’s Engineering Double Degree Program. He has obtained an MBA from University of Strathclyde and has served as a scholar and advisor in technology management since 2008. From FinTech to HealthTech, he has advised over 50 organisations to achieve high growth rate and productivity driven by deep tech adoptions.

Creation date




Organisation type


Certifications & qualifications

BioMind® has been featured in over 120 media globally and has been crowned the Gold winner of Singapore Techblazer Award 2019, top winner of 19th Asia Pacific ICT Alliance Award (ICT & Security), listed as Top 8 innovations in Arab Health 2020 and Top 10 AI Powered Healthcare Companies in APAC by CIO outlook 2019, nominated as semifinalist in EuroMinnies 2020 (“Best New Radiology Software” and “Best New Radiology Vendor”) and winner of COVID-19 detection using AI at World AI Conference (WAIC) 2020.

Trading area

Luxembourg, Greater Region, Europe, International

International locations

Europe, Asia


House of Biohealth 27-29, rue Henri Koch L-4354 Esch/Alzette, Luxembourg



Les cookies participent au bon fonctionnement de ce site internet. En utilisant ce dernier, vous acceptez l’utilisation des cookies. En savoir plus